157 related articles for article (PubMed ID: 38312260)
1. Costs of UK community care for individuals with recessive dystrophic epidermolysis bullosa: Findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study.
Jeffs E; Pillay E; Ledwaba-Chapman L; Bisquera A; Robertson S; McGrath J; Wang Y; Martinez A; Patel A; Mellerio J
Skin Health Dis; 2024 Feb; 4(1):e314. PubMed ID: 38312260
[TBL] [Abstract][Full Text] [Related]
2. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
[TBL] [Abstract][Full Text] [Related]
3. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study.
Mellerio JE; Pillay EI; Ledwaba-Chapman L; Bisquera A; Robertson SJ; Papanikolaou M; McGrath JA; Wang Y; Martinez AE; Jeffs E
Orphanet J Rare Dis; 2023 Aug; 18(1):235. PubMed ID: 37559055
[TBL] [Abstract][Full Text] [Related]
4. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of wound care options in patients with recessive dystrophic epidermolysis bullosa: a costly necessity.
Kirkorian AY; Weitz NA; Tlougan B; Morel KD
Pediatr Dermatol; 2014; 31(1):33-7. PubMed ID: 24224977
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
[TBL] [Abstract][Full Text] [Related]
9. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).
Rogers CL; Gibson M; Kern JS; Martin LK; Robertson SJ; Daniel BS; Su JC; Murrell OGC; Feng G; Murrell DF
JAAD Int; 2021 Mar; 2():134-152. PubMed ID: 34409361
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa.
Feinstein JA; Bruckner AL; Chastek B; Anderson A; Roman J
Orphanet J Rare Dis; 2022 Sep; 17(1):367. PubMed ID: 36175960
[TBL] [Abstract][Full Text] [Related]
11. Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa.
Jeon IK; On HR; Kim SC
Ann Dermatol; 2016 Feb; 28(1):6-14. PubMed ID: 26848213
[TBL] [Abstract][Full Text] [Related]
12. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
[TBL] [Abstract][Full Text] [Related]
14. From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Eichstadt S; Tang JY; Solis DC; Siprashvili Z; Marinkovich MP; Whitehead N; Schu M; Fang F; Erickson SW; Ritchey ME; Colao M; Spratt K; Shaygan A; Ahn MJ; Sarin KY
Clin Cosmet Investig Dermatol; 2019; 12():933-942. PubMed ID: 31920360
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
[TBL] [Abstract][Full Text] [Related]
16. Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series.
Pourani MR; Vahidnezhad H; Mansouri P; Youssefian L; Rakhshan A; Hajimoradi B; Abdollahimajd F; Uitto J
Dermatol Ther; 2022 Jul; 35(7):e15515. PubMed ID: 35420725
[TBL] [Abstract][Full Text] [Related]
17. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing.
Onoufriadis A; Proudfoot LE; Ainali C; Torre D; Papanikolaou M; Rayinda T; Rashidghamat E; Danarti R; Mellerio JE; Ma'ayan A; McGrath JA
Exp Dermatol; 2022 Mar; 31(3):420-426. PubMed ID: 34694680
[TBL] [Abstract][Full Text] [Related]
20. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB).
Bruckner AL; Fairclough DL; Feinstein JA; Lara-Corrales I; Lucky AW; Tolar J; Pope E
Br J Dermatol; 2018 May; 178(5):1128-1134. PubMed ID: 29341069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
